Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Target Price at $20.71

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus rating of “Hold” from the sixteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $20.71.

A number of research firms recently weighed in on HIMS. TD Cowen restated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, Piper Sandler reiterated a “neutral” rating and set a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 101,993 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66. Following the sale, the chief financial officer now directly owns 109,392 shares of the company’s stock, valued at $3,240,191.04. This trade represents a 48.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the sale, the insider now directly owns 159,796 shares in the company, valued at $2,341,011.40. This trade represents a 1.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,153,519 shares of company stock worth $24,486,721. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC boosted its stake in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health during the second quarter valued at about $111,000. CWM LLC boosted its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Quarry LP boosted its stake in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 1.1 %

NYSE HIMS opened at $30.35 on Thursday. The company has a market cap of $6.63 billion, a PE ratio of 68.98 and a beta of 1.06. Hims & Hers Health has a 12 month low of $8.09 and a 12 month high of $35.02. The stock has a 50 day moving average of $21.14 and a 200-day moving average of $19.57.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the business earned ($0.04) EPS. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.